(JP5117193) 1. For topical use is in a subject in the manufacture of the composition Arthrospira-based method, (1) nutritional deficiency or light, dehydration, or about 80% Arthrospira is growth by removing liquids,Arthrospira physiologically stressed electIvely cellulosequick step; and an effective amount of a biocidal action, (2) with respect to the stressed Arthrospira and above (1), to a subject in a carrier suitable for topical administration, in a solvent, base or excipient comprising the step of mixing, wherein the effective amount of a biocidal effects, fungi, bacteria or virus that is the effective amount for stop, wherein the Arthrospira is not freeze-driedmethod. 2. Produced by a method according to claim 1 Arthrospira-based composition. 3. In a subject Eseliericia, bacteria or virus are used as topical Arthrospira-based composition produced by the method of 80%, (1) Arthrospira ACPPE liquid that can be grown in, the step of providing a physiologically stressed Arthrospira stressed Arthrospira and ; (2), adapted to remove contaminants in the washing step and drying the washed Arthrospira of ; (3) is, not lyophilizedstep; after cleaning and (4), and an effective amount of a biocidal action against Arthrospira, carrier suitable for topical administration, solvent, excipient or a mixture of FAPG no addresscomprising quick step. 4. Claim 3 Arthrospira produced by the method of topical use made from the composition. 5. For use as a topical antimicrobial composition comprising, in response to a physiological stress, dried,Arthrospira and an effective amount of the bactericide, suitable for topical administration to a subject in with a carrier, solvent, base or excipient includes, physiological stress, nutrient deficiency or light, dehydration, or about 80% liquids from growing Arthrospira ACPPE achieved by, beforeserial Arthrospira is not freeze-dried composition. 6. The subject, a human, an animal, an agricultural or horticultural product, soil or artificial claim 5 composition selected from the structure. 7. To the subject a topical fungal infection or prevent or treat RNAinto in manufacture of a medicament, for an effective amount of a bactericidal, dried,and physiologically stressed Arthrospira, suitable for topical administration to a subject of the carrier, solvent, base or excipient for the treatment of, physiological stress, nutrient deficiency or light, dewatehng, or a liquid that can be about 80% Arthrospira ACPPE growth achieved by, beforeserial Arthrospira is used which does not freeze-dried. 8. In the manufacture of a topical germicidal composition method , (1) nutritional deficiency or light, dehydration, or about 80% microbial growth Arthrospira by removing liquidsArthrospira in the step of providing a physiological stress; and (2) physiologicalupon receiving a stress, dried, Eseliericia actioneffective amount The (1) and Arthrospira of, suitable for topical administration to the subject a carrier, a solvent, which is a mixture of excipients FAPG comprising, wherein the Arthrospira is not lyophilizedmethod. 9. In response to a physiological stress, dried,Arthrospira and an effective amount of a bactericidal, bacteriostatic agent 1 and at least one synergistic combination, suitable for topical administration to the subject a carrier, solvent, base or excipient includes, physiological stress, nutrient deficiency or light, dehydration, or about 80% liquids Arthrospira ACPPE growth is achieved by, whereinArthrospira is not lyophilized topical antiseptic composition. 10. The bacteriostatic agent, terbinafine, bifonazole, clotrimazole, miconazole, econazole, ketoconazole and tolnaftate claim 9 is selected from the group consisting of topical antiseptic composition. 11. To the subject a topical fungus infection or to prevent or treat RNAinto in manufacture of a medicament, for an effective amount of a bactericidal, dried,physiologically stressed Arthrospira and, at least one of 1 and a bacteriostatic agent, topical administration to the subject in a suitable carrier, solvent, base or excipient for the treatment of, physiological stress, nutrient deficiency or light, dewatehng, or a liquid that can Arthrospira about 80% growth is accomplished by ACPPE,Arthrospira wherein is used not freeze-dried. 12. The bacteriostatic agent is, terbinafine, bifonazole, clotrimazole, miconazole, econazole, ketoconazole and tolnaftate is selected from the group consisting of claim 11. 13. Sterilizing the composition locally method , (1) nutritional deficiency or light, dehydration, or about 80% Arthrospira is growth by removing liquidsphysiological step of applying a stress to the Arthrospira; and (2) dried,upon receiving a stress, an effective amount of the microbicidal The (1) and Arthrospira of, at least one of 1 and a bacteriostatic agent, suitable for topical administration to the subject a carrier, a solvent, base or excipient mixture, and freeze drying the Arthrospira is not step. 14. A dried,in response to a physiological stress, and an effective amount of a bactericidal Arthrospira, applied topically to a subject in a suitable carrier, solvent, base or excipient includes, physiological stress, nutrient deficiency or light, dehydration, or about 80% liquids Arthrospira ACPPE growth is achieved by, whereinArthrospira is not lyophilized topical bactericidal composition. 15. Claim 14 in the subject is a human the composition of the above. 16. To a subject a topical bacterial infection or entry for the manufacture of a medicament for the prevention or treatment, an effective amount of a bactericidal against, dried,and physiologically stressed Arthrospira, suitable for topical administration to the subject a carrier, solvent, base or excipient for the treatment of, physiological stress, nutrient deficiency or light, dewatehng, or a liquid that can Arthrospira about 80% growth is accomplished by ACPPE, whereinArthrospira is used not freeze-dried. 17. The bacterial infection is, use of claim 16 caused by Propionibacterium acne. 18. In the manufacture of a topical germicidal composition method , (1) nutritional deficiency or light, dehydration, or about 80% liquids from growing Arthrospira by removingphysiologically stressing Arthrospira step; and (2) upon receiving a stress, dried,Arthrospira and bactericidal effective amount of the above (1), which is suitable for topical administration to a subject of the carrier, solvent, base or excipient or a mixture of, physiological stress, nutrient deficiency or light, dehydration, or a liquid that can grow is from about 80% Arthrospira ACPPE achieved by, saidArthrospira is not lyophilized step. 19. To mammalian skin for topical use in the treatment or prevention of abnormalities in the composition, of the above compositions is, dried,in response to a physiological stress, and an effective amount of a biocidal action Arthrospira, applied topically to the mammal in a suitable carrier, solvent, base or excipient includes, physiological stress, nutrient deficiency or light, dewatehng, or 80% of the liquid Arthrospira ACPPE growth can be accomplished by,effective amount with respect to said biocidal action, fungi, bacteria or virus to an effective amount, the Arthrospira is not freeze-dried composition. 20. To a mammal for the treatment or prevention of abnormalities in the skin in the manufacture of a medicament, an effective amount of a biocidal action, dried,physiologically stressed Arthrospira and, in a carrier suitable for topical administration to the mammal, solvent, base or excipient for the treatment of, physiological stress, nutrient deficiency or light, dehydration, or 80% and growing the Arthrospira ACPPE liquid which may be achieved by about, according to the effective amount of a biocidal action, fungi, bacteria or viruses in an amount effective to, in the above-mentioned lyophilized Arthrospira is not used. 21. The above-mentioned abnormalities in the skin, pitted, acne damage, rosacea, red portions with, crack, a burn, a water blister, psoriasis, eczema, desquamates Trombiculiasis, wrinkles, a papule, stomatitis, damage, pustules, trauma, neonatal HRTF dermatitis, diaper rash, ulcerations, cold sores, razor surrenders, chickenpox, dermatitis, selected from the group consisting of cracked heels and elbows of claim 20 are used. 22. A dried, physiologically stressed Arthrospira and bactericidal effective amount, to the subject a carrier suitable for local application, solvent, base or excipient includes, physiological stress, nutrient deficiency or light, dehydration, or about 80% liquids Arthrospira ACPPE growth is achieved by, beforeserial Arthrospira is not lyophilized topical antiviral composition. 23. A dried, physiologically stressed Arthrospira and, applied to a subject in a carrier suitable for local, solvent, base or excipient, for the prevention or treatment of a viral infection in a subject locally in the manufacture of a medicament for use, physiological stress, nutrient deficiency or light, dehydration, or about 80% liquids from growing Arthrospira ACPPE achieved by,wherein Arthrospira is used which does not freeze-dried. 24. The manufacturing method of the anti-viral composition comprising , (1) nutritional deficiency or light, dehydration, or a liquid that can grow is from about 80% Arthrospira by removingphysiologically stressed Arthrospira in, (2) an effective amount, to form a dried, The (1) stressed Arthrospira and of, suitable for topical administration to the subject a carrier, solvent, base or excipient comprising the steps of mixing, wherein the Arthrospira is not freeze-dried method. 25. Claim 1 A. maxima is in the Arthrospira.
最新评论
暂无评论。